INIS — what changed in the latest 10-Q
A section-by-section comparison of INIS's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-12 vs the prior 10-Q · 2026-05-20
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +57 | −43 | ~9 | 24 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 1 |
| Legal proceedings | Text added/removed | +1 | −1 | 0 | 0 |
| Risk factors | Some risk factors updated | +1 | −16 | ~1 | 3 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3)
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-12
We are currently in development of the EasyFill Iodine Encapsulation System, a robotic lab device to be paired with our Theranostics Products. The EasyFill is still in the developmental stage. We are targeting a Q1 2027 roll out and Q3 2027 commercial ramp up, including additional sales of I-131. In…
This decrease in sales for the three months and six months ended June 30, 2026 , as compared to the same periods in 2025 was the result of lost sales in our Theranostics Products segment due to the effects from two voluntary product recalls during January and February of 2026 as discussed in more de…
The decrease in cost of product for the three months and six months ended June 30, 2026, as compared to the same periods in 2025 was due to decreased sales overall which was partially offset by adjustments for accounting for labor hours beginning in 2026. We evaluated and updated our policies for cl…
Gross profit for the three months ended June 30, 2026 was $1,359,235, compared to $2,141,559 for the same period in 2025. This represents a decrease in gross profit of $782,324, or approximately 37%, compared to the same period in 2025.
Gross profit for the six months ended June 30, 2026 was $2,510,183, compared to $4,173,596 for the same period in 2025. This represents a decrease in gross profit of $1,663,413, or approximately 40%, compared to the same period in 2025.
Text removed vs the prior filing · source: 10-Q · 2026-05-20
In 2022 we entered a joint venture to develop the EasyFill Automated Capsule System, a robotic lab device to be paired with our Theranostics Products. The EasyFill is still in the developmental stage. We are targeting a Q3 2026 roll out and Q2 2027 commercial ramp up, including additional sales of I…
In 2023, we entered into an asset purchase agreement with AMICI, Inc. to purchase manufacturing molds, device registrations, trademarks, and all production rights to several AMICI, Inc. medical device and accessory products for lung ventilation; this included the Swirler Radioaerosol System and Tru-…
Sale of Product for the three months ended March 31, 2026 was $2,378,924 as compared to $3,238,900 for the same period in 2025, an overall decrease of $859,976, or approximately 27%. This decrease in sales was the result of lost sales in our Theranostics Products segment due to voluntary recalls of …
Cost of product increased to $1,227,976 for the three months ended March 31, 2026 from $1,206,863 for the same period in 2025. This is an increase of $21,113, or approximately 2%. The increase in cost of product was partially due to adjustments for accounting for labor hours beginning in the three m…
The following table presents cost of product and gross profit data for each of our business segments for the three months ended March 31, 2026:
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-12
We are not a party to any legal proceedings. Management is not aware of any legal proceedings proposed to be instituted against us. However, from time to time, we may be subject to claims and litigation generally associated with any business operating in the ordinary course.
Text removed vs the prior filing · source: 10-Q · 2026-05-20
A discussion of legal matters is found in Note 7, “Commitments and Contingencies”, in the accompanying notes to the unaudited condensed consolidated financial statements included in Part I - Item 1. Financial Statements of this Quarterly Report.
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-12
In April 2025, an FDA inspection at our Idaho Falls facility resulted in an Official Action Indicated ("OAI"). RNX developed and implemented corrective actions and submitted our 15-day, 90-day, and 180-day, 270-day, and subsequently submitted our 1-year updates. In response to the FDA Form 483 issue…
Text removed vs the prior filing · source: 10-Q · 2026-05-20
Volatility in raw material and energy costs, interruption in ordinary sources of supply and an inability to recover unanticipated increases in energy and raw material costs from customers could result in lost sales or significantly increase the cost of doing business.
Market and economic conditions affecting the costs of raw materials, utilities, energy costs, and infrastructure required for the delivery of our goods and services are beyond our control and any disruption or halt in supplies, or rapid escalations in costs could affect our ability to manufacture pr…
For instance, an interruption in the supply of isotopes such as cobalt-57, cobalt-60, or iodine-131 could result in lost sales in our Calibration & Reference Products, Cobalt Product, and Theranostics Products segments.
We are in ongoing discussions regarding the long-term viability of some territorial or regional distributors and may need to procure new distributors. If we are unable to do so, we would have a loss of revenue.
We purchase a significant portion of our raw material radioisotopes from overseas suppliers, some of which are government agencies or work with government agencies for the manufacture of radioisotopes. The price and availability of those products could be adversely affected through changes in curren…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice